Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read more
The NHS-Galleri Trial is being launched to evaluate whether a blood test may help identify cancer earlier when combined with
Read more
Amgen’s first-in-class KRAS G12C inhibitor LumykrasTM (sotorasib) has been granted Conditional Marketing Authorisation by the Medicines and Healthcare products Regulatory
Read more
Arvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read more
QIAGEN officially confirmed a global cooperation agreement with Sysmex Corporation for the development and commercialization of cancer companion diagnostics, leveraging
Read more
Nucleai and Merck KGaA will collaborate utilizing Nucleai’s AI-powered platform to develop pathology-based biomarkers as companion diagnostics. Nucleai, a precision
Read more
Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a partnership to advance the early phase clinical development of Aleta’s
Read more
Kite, a Gilead Company, and Shoreline Biosciences have announced a $2.3 Billion strategic partnership to develop novel cell therapies across
Read more
Engine Biosciences, a company deciphering complex biology to unleash impactful therapeutics plans to use funds from a $43 million funding
Read more
The European Commission has approved Astellas’ XTANDI™ (enzalutamide) for men with metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Japanese multinational pharmaceutical company
Read more